Related Experiment Videos
[Lumbar myelography with metrizamid (author's transl)]
Rontgen-Blatter; Zeitschrift Fur Rontgen-Technik Und Medizinisch-Wissenschaftliche Photographie
|March 1, 1977
Summary
Water-soluble Metrizamid (Amipaque R) in lumbar myelography showed mild, transient side effects in 32% of patients. Higher injection levels increased complication risks, but no arachnoiditis was observed.
Area of Science:
- Radiology
- Neurology
- Pharmacology
Context:
- Lumbar myelography is a diagnostic imaging technique.
- Water-soluble contrast media are used in myelography.
- Metrizamid (Amipaque R) is a water-soluble contrast agent.
Purpose:
- To evaluate the safety and efficacy of Metrizamid in lumbar myelography.
- To assess the side effects and contrast quality of Metrizamid.
- To compare Metrizamid with other water-soluble contrast media.
Summary:
- 105 lumbar myelographies were performed using Metrizamid (170 mg I/ml).
- 32% of patients experienced mild, short-duration side effects requiring no treatment.
- No epileptic seizures or arachnoiditis were reported; higher injection levels correlated with increased complication risks.
Impact:
- Metrizamid offers comparable contrast quality to other agents.
- Understanding Metrizamid's side effect profile aids clinical decision-making.
- Identifying risk factors, such as injection level, enhances patient safety in myelography.